BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18339850)

  • 1. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
    Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
    Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
    Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
    Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of the RUNX3 gene in lung cancer.
    Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
    Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
    Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
    Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
    Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
    Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.
    Sanchez-Cespedes M; Decker PA; Doffek KM; Esteller M; Westra WH; Alawi EA; Herman JG; Demeure MJ; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Mar; 61(5):2092-6. PubMed ID: 11280771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer.
    Luxen S; Belinsky SA; Knaus UG
    Cancer Res; 2008 Feb; 68(4):1037-45. PubMed ID: 18281478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
    Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.
    Tanaka K; Imoto I; Inoue J; Kozaki K; Tsuda H; Shimada Y; Aiko S; Yoshizumi Y; Iwai T; Kawano T; Inazawa J
    Oncogene; 2007 Sep; 26(44):6456-68. PubMed ID: 17438526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation.
    Takada H; Imoto I; Tsuda H; Nakanishi Y; Ichikura T; Mochizuki H; Mitsufuji S; Hosoda F; Hirohashi S; Ohki M; Inazawa J
    Oncogene; 2005 Dec; 24(54):8051-60. PubMed ID: 16103878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer.
    Fukui T; Kondo M; Ito G; Maeda O; Sato N; Yoshioka H; Yokoi K; Ueda Y; Shimokata K; Sekido Y
    Oncogene; 2005 Sep; 24(41):6323-7. PubMed ID: 16007200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional epigenomics identifies genes frequently silenced in prostate cancer.
    Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
    Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis.
    Vuillemenot BR; Pulling LC; Palmisano WA; Hutt JA; Belinsky SA
    Carcinogenesis; 2004 Apr; 25(4):623-9. PubMed ID: 14656941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma.
    Belinsky SA; Klinge DM; Liechty KC; March TH; Kang T; Gilliland FD; Sotnic N; Adamova G; Rusinova G; Telnov V
    Carcinogenesis; 2004 Jun; 25(6):1063-7. PubMed ID: 14742312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
    Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
    Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
    Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.